Biocon Biologics Unveils Yesintek: The Biosimilar Game Changer in US Market

Biocon Biologics Limited officially announced the commercial availability of Yesintek™ (ustekinumab-kfce), the biosimilar to Stelara®, on February 24, 2025, in the United States. The announcement was the company's inaugural product launch in the U.S. after its complete transition into an end-to-end global biosimilars enterprise. Yesintek is indicated for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, providing a more affordable option for patients with chronic autoimmune conditions. The biosimilar will be available in all the formulations that are currently offered by Stelara. Biocon stresses its dedication to enhancing patient access to high-quality, affordable medications and has put in place a strong patient assistance program, including benefits verification and copay support.

 

Source: Biocon.com, February 24, 2025